If you would like to receive the daily Market Report by email please fill out your name and email address in the sign-up form below and you will be added to our mailing list.
Monday,17 January 2022 at 16:53
maintains that they are
still keen to purchase Glaxo
SmithKline’s consumer healthcare arm after having a £50 Billion
third offer rejected.
The unscheduled announcement came after Glaxo
SmithKline confirmed over the weekend it had rejected a third
offer for the division which owns the Panadol and Sensodyne brand names.
They said that the offer from Unileverfundamentally undervalued the consumer business and its
prospects, adding that they were still committed to separating the business
from their medical arm and floating it on the London Stock Exchange.
Valuations of GlaxoSmithKline’s consumer healthcare arm by analysts have ranged
from £45bn to £48bn.
UK and European markets
closedhigheras investors digested a string of corporate news
and the latest growth data out of China.
U.S. markets are closed in
observance of Martin Luther King Jr. Day.
Oil prices edged up
as investors bet supply will remain tight amid restrained output by major
producers with global demand unperturbed by the omicron coronavirus variant.
Gold prices held steady
as market participants gauged the global economic policy outlook, with
inflation-based demand for bullion countering hawkish comments from U.S.
Federal Reserve officials, supporting the dollar and Treasury yields.
At the close
FTSE 100 7,611 +0.91%
FTSE 250 22,871 +0.56%
DAX 15,937 +0.34%
Dow Jones 35,911 (-0.56%)
S&P 500 4,662 +0.08%
NASDAQ 14,893 +0.59%
UK 10-YR YIELD 1.191
Gold $1,818 +0.07%
Brent $86.32 +2.69%
Important - No news or research item should be construed as a recommendation to trade. The inclusion of securities within this report does not necessarily imply their suitability for individual portfolios or situations in respect of which further advice should be sought. Information contained in this report has been compiled from sources believed to be reliable but is not warranted to be accurate or complete.